Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Executive Summary

Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.

You may also be interested in...



AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

Roche/Abbvie's Venclexta Outshines Agios IDH Inhibition In AML At ASH

Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.

Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days

Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel